Arvinas Reports Second Quarter 2023 Financial Results and Provides Corporate Update
– Enrollment continues globally in multiple clinical studies of vepdegestrant (ARV-471), including VERITAC-2 2L Phase…
– Enrollment continues globally in multiple clinical studies of vepdegestrant (ARV-471), including VERITAC-2 2L Phase…
– Enrollment continues globally in multiple clinical studies of vepdegestrant (ARV-471), including VERITAC-2 2L Phase…
Development Advisory Committee strengthened with the expertise and leadership of Dr. Yavari TORONTO and HOUSTON,…
Development Advisory Committee strengthened with the expertise and leadership of Dr. Yavari TORONTO and HOUSTON,…
Positive INTERCEPT-AD Phase 1 trial results announced in July 2023 demonstrate ACU193’s potential as a…
Positive INTERCEPT-AD Phase 1 trial results announced in July 2023 demonstrate ACU193’s potential as a…
2Q 2023 ZYNLONTA®1 net sales increased 11% year-over-year; Implemented new go-to-market strategy during the quarter…
2Q 2023 ZYNLONTA®1 net sales increased 11% year-over-year; Implemented new go-to-market strategy during the quarter…
– Preparation underway with GSK for Phase 3 registrational studies evaluating belrestotug and dostarlimab combination – Initiated…
– Preparation underway with GSK for Phase 3 registrational studies evaluating belrestotug and dostarlimab combination – Initiated…
HOUSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company…
HOUSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company…
Essential1OLE: Change in mADL11 from Baseline, By Study week Weekly change from week 8 in…
Essential1OLE: Change in mADL11 from Baseline, By Study week Weekly change from week 8 in…
Phase 3 PATHFNDR-1 Study Topline Data expected in September 2023 Enrollment Completed in Phase 3…
Phase 3 PATHFNDR-1 Study Topline Data expected in September 2023 Enrollment Completed in Phase 3…
– On track to dose first participant in ENTR-601-44 Phase 1 clinical trial in the…
– On track to dose first participant in ENTR-601-44 Phase 1 clinical trial in the…
1H 2023 Revenue Growth of 16% at CER to $180.8M Raising FY 2023 Galafold® Revenue…
1H 2023 Revenue Growth of 16% at CER to $180.8M Raising FY 2023 Galafold® Revenue…